Top entities: Concept Medical, MagicTouch PTA, Ulf Teichgräber, Manish Doshi.

What category does this event fall under?

Tech — classified as medical breakthrough.

What is the sentiment of coverage?

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Tech medical breakthrough

Concept Medical SIRONA Trial Data

Q: When did this event occur?

First reported Apr 27, 2026; last updated Apr 28, 2026.

Q: What is the market impact?

General. The positive preliminary 3-year data for Concept Medical's MagicTouch PTA product could lead to increased adoption of sirolimus-coated balloons in peripheral interventions, potentially impacting the medical device market.

Analysis based on 6 articles · First reported Apr 27, 2026 · Last updated Apr 28, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The positive preliminary 3-year data for Concept Medical's MagicTouch PTA product could lead to increased adoption of sirolimus-coated balloons in peripheral interventions, potentially impacting the medical device market. This development strengthens Concept Medical's position in drug-delivery technologies, which could attract further investment or partnerships in the biotechnology sector.

Medical Devices Biotechnology

Event Summary

Concept Medical Inc. announced the presentation of preliminary 3-year follow-up data from its SIRONA randomised trial at the Charing Cross Symposium 2026. The trial evaluated sirolimus-coated versus paclitaxel-coated balloon angioplasty in femoropopliteal artery disease. The data, presented by Principal Investigator Ulf Teichgräber, showed that MagicTouch PTA, a sirolimus-coated balloon, had higher freedom from clinically driven target lesion revascularization (cdTLR) compared to paclitaxel-coated balloons (88.2% vs 80.2%). These findings suggest that sirolimus-coated balloon angioplasty may provide more durable long-term outcomes. Manish Doshi, Founder and Managing Director of Concept Medical, highlighted the company's commitment to long-term clinical science and generating high-quality data.

Entities Involved

priv

Concept Medical

Concept Medical announced positive preliminary 3-year follow-up data from its SIRONA trial, reinforcing its leadership in drug-delivery technologies and suggesting more durable long-term outcomes for its MagicTouch PTA product.

Importance 100.0 Sentiment 80.0

oth

MagicTouch PTA

MagicTouch PTA, a sirolimus-coated balloon developed by Concept Medical, showed higher freedom from clinically driven target lesion revascularization compared to paclitaxel-coated balloons in the SIRONA trial.

Importance 90.0 Sentiment 75.0

per

Ulf Teichgräber

Ulf Teichgräber, the Principal Investigator, presented the preliminary 3-year SIRONA data, highlighting the sustained reduction in cdTLR with MagicTouch PTA.

Importance 70.0 Sentiment 50.0

per

Manish Doshi

Manish Doshi, Founder and Managing Director of Concept Medical, emphasized the company's focus on generating high-quality, long-term data for clinicians.

Importance 60.0 Sentiment 50.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard